Whole blood point of care metabolic measurement
Ended Project Grant Awarded Last action
- Award ID
- R44HD107897
- Recipient
-
Sequitur Health Corp. UEI NNYXSNYMC545
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,669,086
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date
- Originally
- Funding
-
- $4,031,254.00 Federal
- $637,832.00 Non-federal
- Place of performance
- Arizona, USA
Award details come from USAspending.gov.
Description
- Abstract
- This sbir phase II project will translate phase I technical innovations in sensor materials and a prototype device into a fully functional point of care technology for whole blood biomarker monitoring. IT will culminate in a complete draft of a 510(K) clearance application to the U.S. Food & drug administration (FDA). Currently, no commercial FDA cleared point of care device is available for direct measurement of this biomarker in whole blood. All large clinical instruments require separation of plasma from whole blood via centrifugation prior to measurement. Further, current clinically used measurements, which rely on plasma separated from whole blood, suffer from inaccurate results from pre-analytical variability in sample handling. Phase I completed technical innovations supported by the national science foundation yielded 1) increased sensor specificity, by eliminating signals from interferents, 2) increased sensor sensitivity through sensing material improvements, and 3) direct point of care measurement from whole blood, instead of plasma separated EX-situ from the measurement device which eliminated pre-analytical variability in sample handling. This novel point of care whole blood measurement device will be used to improve at-home management of the ~10,000 people living with these rare metabolic disorders and as a newborn screening to improve identification of the ~1/3500 newborns with rare metabolic disorders out of the 3.9 million annual births in the united states. Ultimately, manufacturing of consumable, single use sensors and sensor readers will create new jobs in the united states. In this direct phase II project, sequitur health corp. Will partner with arizona state university and mayo clinic to innovate a process for mass production of the laboratory-scale sensors developed from the phase I project and subsequently analytically and clinically validate the mass-produced sensors and reader technology for FDA 510(K) clearance.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $196,280 | $0 | |
| Amendment | $703,162 | $0 | |
| Amendment | $196,280 | $0 | |
| Amendment | $196,280 | $0 | |
| Amendment | $196,280 | $0 | |
| Amendment | $633,654 | $0 | |
| Amendment | $633,654 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $637,832 | $0 | |
| Original award | $637,832 | $637,832 |
Show all 14
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Mayo Clinic Arizona | $165,859 | |
| Arizona State University | $160,536 | |
| Mayo Clinic Arizona | $95,724 | |
| Arizona State University | $160,536 |
Quick answers
Who received award R44HD107897?
R44HD107897 was awarded to Sequitur Health Corp. by National Institute of Child Health and Human Development (National Institutes of Health) on September 17, 2021.
How much is award R44HD107897 worth?
$4,669,086 has been obligated on R44HD107897: $4,031,254 in federal funding and $637,832 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award